Introduction: African trypanosomiasis is a neglected tropical disease caused by protozoa Trypanosoma brucei and transmitted via the bite of tsetse fly. The target protein of T. brucei is L-threonine-3-dehydrogenase, which has been selected for this study due to its metabolic importance for the parasite’s survival. The protein was docked with those phytochemicals having in vitro anti trypanosomal activity after passing in silico drug-likeness filters along with standard drug eflornithine and pentamidine available against the disease.
Materials and Methods: A 3D structure of L-threonine-3-dehydrogenasewas downloaded from Protein Data Bank (PDB) with Id: 5K4Y) and Pictorial database of 3D structures in the Protein Data Bank (PDBsum) was used to retrieve the active sites of the protein. The reviewed ligands were screened using SwissADME, Lipinski’s rule of 5, and Molinspiration servers along with standard drugs and docked using AutoDock Vina and AutoDock 4.2.6. The 2D and 3D interacting residues were observed using Discovery Studio.
Results: Ligand Camptothecin which inhibited T. brucei during in vitro cytotoxic assays gave better binding affinity scores than the standard drugs (eflornithine and pentamidine) selected for this study. Camptothecin showed interaction with those active site residues where ligand NAD (nicotinamide-adenine-dinucleotide) binds to the target protein, which is a significant restricting pocket for the hindrance of the parasite.
Conclusions: Camptothecin derived from Camptotheca acuminata trees has the potential to be used as a better alternative than the standard drugs because of its less toxicity, better binding affinity, and specificity towards the inhibition of target protein.